Ion Beam Applications (XBRU:IBAB) ROCE % : 30.64% (As of Dec. 2023)

View and export this data going back to 1998. Start your Free Trial

What is Ion Beam Applications ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ion Beam Applications's annualized ROCE % for the quarter that ended in Dec. 2023 was 30.64%.

Ion Beam Applications ROCE % Historical Data

The historical data trend for Ion Beam Applications's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ion Beam Applications ROCE % Chart

Ion Beam Applications Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

7.48

17.14

4.98

0.90

3.20

Ion Beam Applications Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															8.27	3.78	-2.20	-22.12	30.64

Ion Beam Applications ROCE % Calculation

Ion Beam Applications's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	4.923	/	( ( (623.899 - 461.172)	+	(597.528 - 452.601) )	/ 2 )
	=	4.923	/	( (162.727	+	144.927)	/ 2 )
	=	4.923	/	153.827
	=	3.20 %

Ion Beam Applications's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	42.46	/	( ( (610.241 - 478.044)	+	(597.528 - 452.601) )	/ 2 )
	=	42.46	/	( ( 132.197	+	144.927 )	/ 2 )
	=	42.46	/	138.562
	=	30.64 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Ion Beam Applications (XBRU:IBAB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ion Beam Applications ROCE % Related Terms

Thank you for viewing the detailed overview of Ion Beam Applications's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ion Beam Applications (XBRU:IBAB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ion Beam Applications SA (XBRU:IBAB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

IOBCF:USA 0GZK:UK IOB:Germany

Address

Chemin du Cyclotron, 3, Louvain-La-Neuve, BEL, B-1348

Website

https://www.iba-worldwide.com

Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in two segments: proton therapy and other accelerators and dosimetry. Proton therapy and other accelerators business contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, and the Rest of the World, with REst-of-World sales generating the largest proportion of revenue.

Ion Beam Applications (XBRU:IBAB) Headlines

No Headlines